Sk Biopharmaceuticals Co., Ltd. (326030)
KRX
91,600.00
+7,200.00 (+8.53%)
Closed
Aug 26, 2026
Day's Range
84,800.0094,800.00
52 wk Range
73,000.00144,100.00
Financial Statements - 326030 - Sk Biopharmaceuticals Co., Ltd.
Revenue
706.74B▲ 29.1%
Net Income
253.25B▲ 11.6%Net Margin 35.8%
EBITDA
183.33B▲ 66.5%
Free Cash Flow
146.82B▲ 80.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 706.74B | 547.59B | 354.89B | 246.17B | 418.64B | 25.99B |
| Cost of Goods | 42.90B | 43.10B | 34.08B | 37.76B | 22.33B | 1.97B |
| Gross Profit | 663.83B | 504.49B | 320.80B | 208.41B | 396.30B | 24.02B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 203.93B | 96.33B | -37.52B | -131.07B | 94.95B | -239.49B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 150.88B | 72.59B | -43.85B | -142.46B | 71.27B | -239.90B |
| Income Tax | -102.36B | -154.37B | -8.47B | -3.03B | 6.43B | 7.50B |
| Net Income | 253.25B | 226.97B | -35.37B | -139.43B | 64.84B | -247.41B |
| EPS Basic | 3.40K | 3.07K | -420 | -1.78K | 828 | -3.44K |
| EPS Diluted | 3.40K | 3.07K | -420 | -1.78K | 828 | -3.44K |
| Basic Shares Outstanding | 78.30M | 78.31M | 78.29M | 78.33M | 78.31M | 71.75M |
| Diluted Shares Outstanding | 78.30M | 78.31M | 78.29M | 78.33M | 78.31M | 71.75M |
| Ebit | 158.57B | 83.27B | -35.57B | -138.75B | 72.22B | -235.44B |
| Ebitda | 183.33B | 110.09B | -11.38B | -113.11B | 85.88B | -226.53B |
| Net Income Continuous Operations | 253.25B | 226.97B | -35.37B | -139.43B | 64.84B | -247.41B |
| Minority Interests | 13.69B | 13.76B | 2.49B | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
